Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CD34+ Human Hematopoietic Stem Cells Modified Using Transformer Base Editor in Participants With Severe Sickle Cell Disease

NCT06565026 is registered in ClinicalTrials.gov with CorrectSequence Therapeutics Co., Ltd as lead sponsor.

NCT NCT06565026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06565026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CD34+ Human Hematopoietic Stem Cells Modified Using Transformer Base Editor in Participants With Severe Sickle Cell Disease
Lead sponsor
CorrectSequence Therapeutics Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 2, 2024
Completion date
June 30, 2027
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease